دورية أكاديمية
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
| العنوان: | Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer |
|---|---|
| المؤلفون: | Provencio Pulla, Mariano, Nadal, Ernest, González Larriba, Jose Luís, Martínez Martí, Alex, Bernabé, Reyes, Bosch Barrera, Joaquim, Casal Rubio, Joaquín, Calvo, Virginia, Insa, Amelia, Ponce, Santiago, Reguart, Noemí, De Castro, Javier, Mosquera, Joaquín, Cobo, Manuel, Aguilar, Andrés, López Vivanco, Guillermo, Camps, Carlos, López Castro, Rafael, Morán, Teresa, Barneto, Isidoro, Rodríguez Abreu, Delvys, Serna Blasco, Roberto, Benítez, Raquel, Aguado de la Rosa, Carlos, Palmero, Ramón, Hernando Trancho, Florentino, Martín López, Javier, Cruz Bermúdez, Alberto, Massuti, Bartomeu, Romero Alfonso, Atocha |
| سنة النشر: | 2023 |
| المجموعة: | Universitat de València: Roderic - Repositorio de contenido libre |
| مصطلحات موضوعية: | Càncer |
| الوصف: | BACKGROUND Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients. METHODS In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety. RESULTS A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P=0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan-Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan-Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%). CONCLUSIONS In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | New England Journal of Medicine, 2023; Provencio Pulla, Mariano Nadal, Ernest González Larriba, Jose Luís Martínez Martí, Alex Bernabé, Reyes Bosch Barrera, Joaquim Casal Rubio, Joaquín Calvo, Virginia Insa, Amelia Ponce, Santiago Reguart, Noemí De Castro, Javier Mosquera, Joaquín Cobo, Manuel Aguilar, Andrés López Vivanco, Guillermo Camps, Carlos López Castro, Rafael Morán, Teresa Barneto, Isidoro Rodríguez Abreu, Delvys Serna Blasco, Roberto Benítez, Raquel Aguado de la Rosa, Carlos Palmero, Ramón Hernando Trancho, Florentino Martín López, Javier Cruz Bermúdez, Alberto Massuti, Bartomeu Romero Alfonso, Atocha 2023 Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer New England Journal of Medicine; https://hdl.handle.net/10550/89125Test; 161070 |
| DOI: | 10.1056/NEJMoa2215530 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa2215530Test https://hdl.handle.net/10550/89125Test |
| حقوق: | open access |
| رقم الانضمام: | edsbas.DD379711 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/NEJMoa2215530 |
|---|